1. Crump KS, et al. Fundamental carcinogenic processes and their implications for low-dose risk assessment. Can Res. 1976;36(9):2973–9.
2. Delean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves - application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978;235(2):E97–102.
3. Holford N. Pharmacodynamic principles and the time course of delayed and cumulative drug effects. Transl Clin Pharmacol. 2018;26(2):56–9.
4. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997;35(10):401–13.
5. Macdougall J. Analysis of dose–response studies—E max model. In: Ting N, editor. Dose Finding in Drug Development. Statistics for Biology and Health. New York: Springer; 2006. p. 127–145.